The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

Share Price Information for Directa Plus (DCTA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.20
Bid: 18.40
Ask: 20.00
Change: 0.00 (0.00%)
Spread: 1.60 (8.696%)
Open: 19.20
High: 19.20
Low: 19.20
Prev. Close: 19.20
DCTA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

23 Jun 2021 07:00

RNS Number : 7561C
Directa Plus PLC
23 June 2021
 

23 June 2021

 

Directa Plus plc

("Directa Plus" or the "Company")

 

AGM Statement

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, provides an update on the current financial year to 31 December 2021 ahead of its Annual General Meeting to be held later today in Italy due to covid restrictions.

 

At the time of the announcement of the 2020 final results, the Company reported a strong performance in the first four months of 2021 with revenues increased by almost 50 per cent year-on-year to €2.8m. The Board is pleased to report that this strong revenue growth is continuing in the last two months of the current first half and that the Company is trading in line with market expectations. In the environmental vertical, growth momentum is continuing at the Group's subsidiary, Setcar, which is also benefitting from customer demand driven by the higher prices for oil reclaimed from its remediation services. In the emerging batteries vertical, the Board continues to be pleased with the progress being made with our partner NexTech in Li-S batteries.

 

Overall, the global market for graphene is estimated by different market research to be growing at a compound annual growth rate above 30 per cent, with a particular focus on high quality, sustainably produced graphene such as that produced by Directa Plus.

 

The Company continues to develop both its production technology and suitable applications for its products. This is reflected in the growing IP portfolio which now comprises 55 granted patents alongside an ever-deeper base of know-how covering the core production technology as well as the products launched or being developed by customers.

 

Directa Plus continues to explore new vertical markets and is in negotiations with additional potential partners.

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

Giorgio Bonfanti, CFO

Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald

Pete Lynch

 

 

 

N+1 Singer (Joint Broker)

+44 20 7496 3069

Rick Thompson

Phil Davies

 

 

 

Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson

Heather Armstrong

 

 

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product), textiles (based on our G+® products) and, more recently, lithium-sulphur batteries. In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+® products. All our products are hypoallergenic, non-toxic and sustainably produced.

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMEASKAASNFEFA
Date   Source Headline
15th Apr 20243:01 pmRNSNotification of major holdings
12th Apr 20247:00 amRNSGiPave® installed at Imola Circuit
25th Mar 20247:00 amRNSEUR 1,000,000 Loan Agreement Signed
22nd Mar 20247:00 amRNSCollaboration with UK-based Heathcoat Fabrics
26th Feb 20247:00 amRNSAcquisition of 49% minority interest in Setcar
31st Jan 20247:00 amRNSContract win with FORD Otosan
20th Dec 20237:00 amRNSAcquisition of groundbreaking technology
15th Dec 202311:44 amRNSExpansion of collaboration with Miguel Caballero
10th Nov 20237:00 amRNSChange of Nominated Adviser
27th Sep 20237:00 amRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic collaboration with The SPECTRUM Group
8th Sep 20237:00 amRNSNotice of Interim Results
7th Sep 20237:00 amRNSSignificant contract secured with LIBERTY Galati
19th Jul 20237:00 amRNSProject tender awarded
29th Jun 20237:00 amRNSDirecta Plus receives two new Italian patents
22nd Jun 20237:00 amRNSNew concept for produced water decontamination
15th Jun 20235:40 pmRNSResult of AGM
8th Jun 20237:00 amRNSNew product launch
19th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
10th May 20237:00 amRNSFinal Results
9th May 20237:00 amRNSNew contract with customer Alfredo Grassi
27th Apr 20237:00 amRNSNotice of Results Presentations
20th Mar 20237:00 amRNSNew Patent Granted
27th Feb 20237:00 amRNSTrading Update and Notice of Results
21st Dec 20227:00 amRNSNew significant contract with Pigmentsolution
5th Dec 20222:05 pmRNSSecond Price Monitoring Extn
5th Dec 20222:00 pmRNSPrice Monitoring Extension
2nd Dec 20227:00 amRNSTrading Update
29th Nov 20227:00 amRNSGrant Award
21st Nov 20227:00 amRNSDirectorate Change
28th Oct 20227:00 amRNSFirst Commercial Contract in Latin America
21st Oct 20227:00 amRNSFirst Major Commercial Contract for Gipave
17th Oct 20227:00 amRNSBoar Changes
17th Oct 20227:00 amRNSBoard Changes
29th Sep 202211:05 amRNSSecond Price Monitoring Extn
29th Sep 202211:00 amRNSPrice Monitoring Extension
29th Sep 20227:00 amRNSHalf-year Report
1st Sep 20227:00 amRNSTrading Statement
30th Aug 20227:00 amRNSUS Patent Notice
4th Aug 20227:00 amRNSPartnership Extension and US Patent Award
19th Jul 20227:00 amRNSAgreement with REDA Energy for Grafysorber
5th Jul 20227:00 amRNSSupply Agreement
22nd Jun 20227:00 amRNSGrant of Italian Filtration Patent
17th Jun 20223:40 pmRNSResult of AGM
17th Jun 20227:00 amRNSAGM Statement
19th May 20227:00 amRNSPosting of Annual Report and Notice of AGM
5th May 20227:00 amRNSFinal Results
22nd Apr 20227:00 amRNSPartnership to Develop Automotive Fabrics
4th Apr 20227:00 amRNSUS EPA Authorises Grafysorber for Use in US
7th Mar 20227:00 amRNSOxfordshire Starts Second Trial of GiPave

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.